Ensitrelvir (Xocova)
What studies of Ensitrelvir (Xocova) found
At a glance, by condition
Preventing long COVID: B May help
Based on the strongest evidence, the placebo trial (low certainty): 2 findings, all B.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Ensitrelvir (Xocova) may help for preventing long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- Ensitrelvir (Xocova) · Preventing long COVID is hereBMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Preventing long COVID
Symptoms
Cognition (brain fog)1 study · 253 people took Ensitrelvir (Xocova) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people, or how many isn't reported.
The placebo trial1 study · 5 days · 125 mg (375 mg on Day 1), once-daily for 5 days (few people)
Cognition (brain fog) improved more than in the comparison group.
Ensitrelvir (Xocova) may improve cognition (brain fog) later, when given during acute COVID. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people, or how many isn't reported
See the 1 study
-
P-2044. Analysis of Post COVID-19 Condition After Ensitrelvir Treatment in Asymptomatic or Mild-Symptoms Only Patients in the SCORPIO Phase2b/3 Study (2025)
- People in the study
- —
- Dose
- 125 mg (375 mg on Day 1), once-daily for 5 days
- Outcome
- proportion of patients with PCC on Day 337 for any of the 4 neurological symptoms
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Overall symptoms2 studies · 271 people took Ensitrelvir (Xocova) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people, or how many isn't reported.
The placebo trial1 study · 5 days · 125 mg (375 mg on Day 1), once-daily for 5 days (few people)
Overall symptoms improved more than in the comparison group.
Ensitrelvir (Xocova) may improve overall symptoms later, when given during acute COVID. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people, or how many isn't reported
Studies with no comparison group18 in the study · 5 days · 375 mg loading dose, followed by 125 mg daily, 5-day oral regimen
Overall symptoms improved.
The evidence is very uncertain about the effect of ensitrelvir (Xocova) on overall symptoms later, when given during acute COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (18 in all)
See the 2 studies
-
P-2044. Analysis of Post COVID-19 Condition After Ensitrelvir Treatment in Asymptomatic or Mild-Symptoms Only Patients in the SCORPIO Phase2b/3 Study (2025)
- People in the study
- —
- Dose
- 125 mg (375 mg on Day 1), once-daily for 5 days
- Outcome
- Proportion of patients with PCC on Day 337 for any of the 27 symptoms
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 18 in the study
- Dose
- 375 mg loading dose, followed by 125 mg daily, 5-day oral regimen
- Outcome
- symptoms resolved following ensitelvir treatment
- Effect
- better
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
125 to 375 mg at the start
- 2Top dose
Most often 125 mg (2 of 3 studies)
Doses across 3 studies
125 to 125 mg. One study of 18 people went up to 375 mg.
Each study’s dose, as printed
- 125 mg (375 mg on day 1), once daily Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial. (2024)
- 375 mg loading dose, followed by 125 mg daily, 5-day oral regimen Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series. (2024)
- 125 mg (375 mg on Day 1), once-daily for 5 days P-2044. Analysis of Post COVID-19 Condition After Ensitrelvir Treatment in Asymptomatic or Mild-Symptoms Only Patients in the SCORPIO Phase2b/3 Study (2025)
All papers
- P-2044. Analysis of Post COVID-19 Condition After Ensitrelvir Treatment in Asymptomatic or Mild-Symptoms Only Patients in the SCORPIO Phase2b/3 Study2025 · placebo trial
Summary
This multinational, multicenter, randomized, double-blind, placebo-controlled study, conducted in 2022, examined whether ensitrelvir reduced Post COVID-19 Condition (PCC) in people with asymptomatic or mild COVID-19 who were screened but not enrolled in the Phase3 SCORPIO-SR study. The number of patients with mild COVID-19 symptoms was 350 and the number of asymptomatic participants was 34. Participants were randomized (1:1:1) to orally receive once-daily ensitrelvir 125 mg (375 mg on Day 1), 250 mg (750 mg on Day 1), or placebo for 5 days; 124, 129 and 131 patients were assessed in the ensitrelvir 125 mg, 250 mg and placebo groups. PCC was defined as a condition reported as “not returned to pre-COVID health” with at least one mild/more severe symptom among prespecified 27 symptoms on Day 85, 169, and 337. On Day 337, the proportion with PCC for any of the 27 symptoms was 3.5%, 3.4% and 8.8% in the ensitrelvir 125 mg, 250 mg and placebo groups; risk reductions versus placebo were 60.5% and 61.1%. For any of the 4 neurological symptoms the proportions were 1.7%, 2.6% and 6.4%, with risk reductions of 72.8% and 59.9%. Among asymptomatic participants (9, 13 and 12), 2 participants had PCC. Harms and withdrawals for harms were not reported. The authors state it is suggested that ensitrelvir treatment may reduce PCC in this limited subpopulation with asymptomatic/mild disease.
- Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.2024 · placebo trial
Summary
This exploratory analysis of the double-blind, phase 3 SCORPIO-SR trial assessed whether ensitrelvir prevents post coronavirus disease 2019 (COVID-19) condition (PCC). Patients with mild-to-moderate COVID-19 were randomized (1:1:1) within 120 h of symptom onset to 5-day oral ensitrelvir 125 mg (375 mg on day 1), ensitrelvir 250 mg (750 mg on day 1), or matching placebo once daily. Typical PCC symptoms were assessed with a self-administered questionnaire. In total, 341, 317, and 333 patients were assessed in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively. On days 85, 169, and 337, ensitrelvir 125 mg showed risk reductions versus placebo of 32.7% (95% CI -30.6, 66.1), 21.5% (95% CI -37.3, 55.6), and 24.6% (95% CI -43.7, 60.9) for any of the 14 acute-phase COVID-19 symptoms; ensitrelvir 250 mg showed risk reductions of 10.9% (95% CI -67.0, 52.8), 9.5% (95% CI -56.6, 48.0), and 30.6% (95% CI -36.2, 65.5) on the same days. The reported confidence intervals included zero. Risk reductions were observed in any of the 4 neurological symptoms and were more pronounced among patients with high acute-phase symptom scores at baseline and among those with a baseline body mass index ≥25 kg/m2. Harms, withdrawals, and worsening were not reported. Trial registration jRCT2031210350.
- Early-Phase Oral Antiviral Use and Post-COVID-19 Condition in Outpatients.2026 · compared with another group · 8,657 in the study · 7,699 with outcome data
Summary
This prospective, nationwide, multicenter, registry-based cohort study enrolled outpatients with laboratory-confirmed COVID-19 at 51 acute-care hospitals in Japan. Of 8657 participants in the full analysis population, 7699 were included in the primary analysis population: 2181 received early oral antivirals (1698 ensitrelvir, 98 nirmatrelvir, 385 molnupiravir) and 5518 received no antiviral. Treatment duration was not reported. Follow-up assessments were at day 28 and day 84. The primary outcome was post–COVID-19 condition (PCC), defined as persistence of 1 or more of 5 prespecified symptoms with the same symptoms reported on both day 28 and day 84. Adjusted PCC risk was 21.5% with antivirals and 25.1% without antivirals (adjusted risk ratio 0.86; 95% CI 0.78 to 0.93; P < .001). For individual agents, ensitrelvir had an adjusted risk ratio of 0.86 (95% CI 0.79 to 0.95) and molnupiravir 0.81 (95% CI 0.67 to 0.98); nirmatrelvir had an adjusted risk ratio of 0.88 (95% CI 0.63 to 1.24; P = .47), which the authors report did not reach statistical significance. Failure to return to usual health by day 84 occurred in 9.9% versus 12.9% (adjusted risk ratio 0.77; 95% CI 0.67 to 0.89). For ensitrelvir, this was 9.7% versus 12.9% (adjusted risk ratio 0.75; 95% CI 0.64 to 0.88). Harms and withdrawals due to harms were not reported. Missing outcome data excluded 934 participants. The authors state that the observational design precludes causal inference and residual confounding cannot be excluded.
- Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series.2024 · case report · 18 in the study
Summary
This retrospective case series evaluated real-world use of ensitrelvir in 18 symptomatic, vaccinated outpatients with mild-to-moderate SARS-CoV-2 infection (15 men; median age 39.5 years; range 26–56) between December 1, 2022, and January 31, 2023. Patients received a 5-day oral ensitrelvir regimen (375 mg loading dose, followed by 125 mg daily). There was no control arm; outcomes were compared with historical control data. Nasal swabs were collected on days 0, 3, 6, and 9 for RT-qPCR, and patients were followed for up to 60 days for post-acute sequelae of COVID-19 (PASC). Symptoms such as mild fever and sore throat improved rapidly after one day; 66% of patients recovered within six days. 33% improved within two days and another 33% between days 3 and 6. One patient had a mild cough and five others had mild sore throat for over six days. Mean Ct was 21.82 at symptom onset and 37.65 on day six; 10 patients had Ct over 35 within six days. SARS-CoV-2 RNA became undetectable in one patient on day 3, two on day 6, and twelve on day 9. Compared with historical controls (median 8.5 days), >66% had symptoms resolved in 1.4 days (95% CI 1–6 days). No adverse events, viral rebound, recurrence, or PASC symptoms were observed. Limitations included a relatively small cohort size and qPCR not reflecting infectious virus.
- CROI 2023: Acute and Post-Acute COVID-19.2023 · review
Summary
This invited review summarized studies presented at CROI 2023 on acute COVID-19 and long COVID; it did not conduct its own study or enrol participants. It covered randomized trials and observational analyses, including a peginterferon lambda trial with more than 1900 mostly vaccinated, high-risk, nonhospitalized participants, an inhaled interferon-β1A trial with approximately 220 participants, a nirmatrelvir/ritonavir analysis of approximately 8000 propensity-matched people in the US Veterans Affairs health system, and 40 children treated in Rome. Ensitrelvir, given within 72 hours of symptom onset versus placebo, was associated with shortened symptom and infectious viral shedding duration by approximately 1 day each; at 6 months there was a 25% reduction in any long COVID symptoms and 26% in neurologic symptoms. Metformin was associated with higher odds of undetectable viral RNA at days 5 and 10 (OR, 1.355; 95% CI, 1.054-1.742) and a 42% reduction in long COVID through month 10. Nirmatrelvir/ritonavir was associated with a 98% relative reduction in hospitalization within 14 days versus no therapy. Peginterferon lambda was associated with a 58% risk reduction of hospitalization or emergency department visit within 3 days. Molnupiravir was not associated with significant reduction in hospitalization or death within 30 days versus no therapy; inhaled interferon-β1A did not accelerate RNA clearance over 2 weeks; amubarvimab plus romlusevimab had no effect on long COVID symptoms or quality of life at 36 weeks. Among 40 children, 5 adverse events occurred. Worsening and discontinuation counts were not reported. The authors stated that more data are needed.